表紙
市場調査レポート

新興市場における医療市場アクセス:HTA (医療技術評価)

Access in Emerging Markets: HTA is Making Inroads

発行 Datamonitor Healthcare 商品コード 342051
出版日 ページ情報 英文 119 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
新興市場における医療市場アクセス:HTA (医療技術評価) Access in Emerging Markets: HTA is Making Inroads
出版日: 2015年04月16日 ページ情報: 英文 119 Pages
概要

厳しい競合環境と成長率の低下に直面し、多くの製薬企業は新興市場を収益成長の源として見ています。新興諸国は保険対象範囲の拡大と医療制度インフラへの投資によって医療アクセスを改善しようと努めていますが、資源が限られているため、需要の調整方法を発見することが必要となっています。結果として、政府と政策立案者はHTA (医療技術評価)を活用し始めており、この新しい動向は市場アクセス環境および製薬会社と主要ステークホルダーの関わり方を変化させています。

当レポートでは、新興市場における医療市場へのアクセスの改善に利用されるHTA (医療技術評価) について取り上げ、HTA利用の促進因子・阻害因子、HTAの多様な実施方法、HTAとステークホルダーの関わり、および各国におけるHTAの動向などを分析しています。

エグゼクティブサマリー

HTA利用の促進因子・阻害因子

  • 医療成長の抑制がHTAのニーズを促進
  • 効果的なHTAの利用にとって数多くの障壁が残る
  • HTAの利用がもたらす困難な市場アクセス条件
  • 参考文献

さまざまな方法で実施されるHTA

  • HTAは国のニーズ・好みによってさまざまな方法で導入・実施される
  • 国際的な協力がHTAの発展を形成し、新興市場における機能を構築するが、多様性が残る
  • 参考文献

製薬会社によるHEOR (医療組織) への投資が拡大

  • 公共セグメントにおける医薬品売上の拡大は戦略の変化を余儀なくする
  • 新興市場において製薬会社のHEORへの投資が拡大しているが、ROIの最大化には実用的なアプローチが必要
  • 参考文献

HTAとステークホルダーの関わり

  • 公式なHTAアドバイスチャネルは技術側面にフォーカス
  • ステークホルダーと政策立案者の非公式な関係は当たり前
  • 官民提携は政府とプロバイダーとの幅広い関係へ機会を示す
  • 参考文献

ブラジル

中国

メキシコ

ポーランド

韓国

台湾

目次
Product Code: DMKC0138547

Faced with tough competitive conditions and declining growth rates, many pharma companies are looking towards emerging markets as sources of revenue growth. Growing economies and a burgeoning middle class, as well as expanding healthcare systems, have resulted in high growth rates and increased demand for Western medicines.

However, as developing countries strive to improve access to healthcare by expanding insurance coverage and investing in healthcare system infrastructure, growing patient expectations are increasingly forcing them to find a way of reconciling demand with limited resources. Consequently, governments and policymakers have begun to utilize health technology assessment to this end, and this new trend has changed the market access landscape and the way in which pharma interacts with key stakeholders.

This report addresses the following questions:

  • How is HTA use impacting access in emerging markets?
  • What are the differences between HTA use in different emerging market countries?
  • How have pharma's strategies adapted in reaction to the changes brought about by HTA?
  • What channels exist for pharma-HTA engagement?
  • What are the key lessons for success in overcoming hurdles presented by HTA in emerging markets?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

DRIVERS AND RESISTORS OF HTA USE

  • 1. Healthcare growth containment drives need for HTA
  • 2. A number of obstacles remain to effective HTA use
  • 3. More challenging market access conditions are resulting from HTA use
  • 4. Bibliography

HTA IS IMPLEMENTED IN A VARIETY OF WAYS

  • 5. HTA is adopted and implemented in a variety of ways depending on a country's needs and Preferences
  • 6. International collaboration is shaping HTA development and capacity building in emerging markets, but variations will remain
  • 7. Bibliography
  • PHARMA'S INVESTMENT IN HEOR IS GROWING
  • 8. Growing pharma sales in the public segment necessitate shift in strategy
  • 9. Pharma's investment in HEOR in emerging markets is growing, but a pragmatic approach is critical to maximize ROI
  • 10. Bibliography

HTA AND STAKEHOLDER ENGAGEMENT

  • 11. Formal HTA advice channels focus on technical aspects
  • 12. Informal engagement of stakeholders and policy makers is commonplace
  • 13. Public-private partnerships present an opportunity for wider engagement with governments and providers
  • 14. Bibliography

BRAZIL

  • 15. Brazil has established itself as a leader in HTA in Latin America
  • 16. Universal healthcare coverage necessitated introduction of a formal HTA process
  • 17. Establishment of CONITEC represents a major step in strengthening HTA process in Brazil
  • 18. Communication with CONITEC focuses on the technical checking of the dossiers, but the agency is open to further engagement
  • 19. Threat of spill-over effect into private insurance coverage enhances importance of CONITEC approval
  • 20. Bibliography

CHINA

  • 21. China lags behind in its capacity to use HTA, but slow change is set to occur
  • 22. Universal health insurance coverage as a result of healthcare reforms
  • 23. Bibliography

MEXICO

  • 24. HTA in Mexico lags behind Brazil
  • 25. The Mexican health insurance system is fragmented
  • 26. The CSG is the key HTA body in Mexico and decides on national reimbursement
  • 27. Bibliography

POLAND

  • 28. Poland is a leader in HTA in Central and Eastern Europe
  • 29. Public health insurance provides coverage to 98% of the Polish people
  • 30. Bibliography

SOUTH KOREA

  • 31. South Korea's HIRA has emerged as the leader in HTA in the Asia Pacific region
  • 32. South Korea's health insurance system is based on a single major payer
  • 33. HIRA and NECA are the key HTA bodies in South Korea
  • 34. Bibliography

TAIWAN

  • 35. Taiwan has introduced HTA, but has limited capacity to carry out full assessment
  • 36. The Taiwanese healthcare system has a single payer
  • 37. The pricing and reimbursement process was reformed in 2013
  • 38. Bibliography
Back to Top